<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00412880</url>
  </required_header>
  <id_info>
    <org_study_id>1216.11</org_study_id>
    <nct_id>NCT00412880</nct_id>
  </id_info>
  <brief_title>BI 2536 Second Line Monotherapy in SCLC</brief_title>
  <official_title>An Open-label Phase II Trial to Investigate the Efficacy, Safety, and Pharmacokinetics of a Single Dose of 200 mg i.v. BI 2536 Administered Every 21 Days in Patients With Sensitive Relapse Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      Open label, uncontrolled Phase II trial to assess the efficacy and safety of BI 2536 in
      second line treatment in sensitive-relapse SCLC patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Objective tumor response evaluated according to the RECIST criteria by tumor measurements using standard imaging (CT, MRI)</measure>
    <time_frame>at least 6 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>at least 6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>at least 6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of overall response</measure>
    <time_frame>at least 6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence and intensity of adverse events graded according to CTCAE</measure>
    <time_frame>at least 6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of dose limiting toxicity</measure>
    <time_frame>at least 6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with significant abnormalities in laboratory parameters</measure>
    <time_frame>36 weeks</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">23</enrollment>
  <condition>Carcinoma, Small Cell</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 2536</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Inclusion Criteria:

          -  Patients with histologically or cytologically confirmed, -sensitive-relapse- SCLC
             defined by a relapse 60 days or more after cessation of prior first-line chemotherapy.

          -  Patients with at least one measurable lesion, with longest diameter to be recorded as
             20 mm or greater.

          -  Life expectancy of at least three months and ECOG performance score of 2 or less and
             written informed consent that must be consistent with ICH-GCP Guidelines.

        Exclusion Criteria:

        Exclusion Criteria:

          -  More than one prior regimen of chemotherapy, mixed small cell/large cell or combined
             small cell histology.

          -  Symptomatic brain metastases or leptomenigeal disease

          -  Patients with ascites, patients who have any other life-threatening illness or organ
             system dysfunction, or other malignancies diagnosed within the past five (5) years
             (other than non melanomatous skin cancer)

          -  Absolute neutrophil count (ANC) &lt;1,500/µl, platelet count &lt;100,000/µl, or hemoglobin
             &lt;9 mg/dl

          -  Total bilirubin &gt;1.5 x ULN, aspartame amino transferase (AST) and/or alanine amino
             transferase (ALT) &gt;2.5 x ULN, or aspartate amino transferase (AST) and/or alanine
             amino transferase (ALT) &gt;5 x ULN in case of known liver metastases, serum creatinine
             &gt;2.0 mg/dl (&gt;176 µmol/L, SI Unit equivalent)

          -  Chemo-, hormone- (other than Megace®) or immunotherapy within the past 4 weeks or
             within less than 4 half-life times of the previous drug prior to treatment with the
             trial drug

          -  Radiation therapy within the past 2 weeks prior to or during treatment with the trial
             drug

          -  Patients with any serious active infection (i.e., requiring an IV antibiotic,
             antifungal, or antiviral agents), patients with known HIV, hepatitis-B or -C infection

          -  Known or suspected active drug or alcohol abuse

          -  Treatment with any other investigational drug within the past 4 weeks or within less
             than 4 half-life times of the investigational drug

          -  Patients with a known pre-existing coagulopathy or requiring therapeutic
             anticoagulation with warfarin (Coumadin ®)

          -  Patients with neuropathy (sensory or motor) CTCAE 3
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1216.11.007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Fayetteville</city>
        <state>Arkansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1216.11.003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1216.11.006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Evanston</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1216.11.002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1216.11.005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1216.11.001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1216.11.011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1216.11.010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1216.11.012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1216.11.009 Alberta Cancer Board</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 18, 2006</study_first_submitted>
  <study_first_submitted_qc>December 18, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 19, 2006</study_first_posted>
  <disposition_first_submitted>April 30, 2014</disposition_first_submitted>
  <disposition_first_submitted_qc>April 30, 2014</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">May 16, 2014</disposition_first_posted>
  <last_update_submitted>April 30, 2014</last_update_submitted>
  <last_update_submitted_qc>April 30, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 16, 2014</last_update_posted>
  <responsible_party>
    <name_title>Boehringer Ingelheim, Study Chair</name_title>
    <organization>Boehringer Ingelheim</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Small Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

